Dose-response profiles for combined treatments with sorafenib and the SENP1 inhibitor are plotted in Fig. 7A, and corresponding IC50 values were calculated and are summarized in Fig. 7B. These results demonstrate that SENP1 inhibition sensitized both naïve and sorafenib-resistant HCC cells to sorafenib treatment. Here, SENP1 is linked to hepatocellular carcinoma.